| SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Karel HEJDUK, Miloš PEŠEK, Vítězslav KOLEK, Leona KOUBKOVÁ, Jaromír ROUBEC, Markéta ČERNOVSKÁ, František SALAJKA, Jana KREJČÍ, Libor HAVEL, Marcela TOMÍŠKOVÁ, Monika ŠATÁNKOVÁ, Andrea BENEJOVÁ, Ivona GRYGÁRKOVÁ, Michal HRNČIARIK, Milada ZEMANOVÁ, Dimka SIXTOVÁ and Zdeněk MERTA. Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic. In ERS international Congress 2017. 2017. ISSN 0903-1936. |
Other formats:
BibTeX
LaTeX
RIS
@proceedings{1400030,
author = {Skřičková, Jana and Chloupková, Renata and Hejduk, Karel and Pešek, Miloš and Kolek, Vítězslav and Koubková, Leona and Roubec, Jaromír and Černovská, Markéta and Salajka, František and Krejčí, Jana and Havel, Libor and Tomíšková, Marcela and Šatánková, Monika and Benejová, Andrea and Grygárková, Ivona and Hrnčiarik, Michal and Zemanová, Milada and Sixtová, Dimka and Merta, Zdeněk},
booktitle = {ERS international Congress 2017},
keywords = {NSCLC},
language = {eng},
title = {Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic},
year = {2017}
}
TY - CONF
ID - 1400030
AU - Skřičková, Jana - Chloupková, Renata - Hejduk, Karel - Pešek, Miloš - Kolek, Vítězslav - Koubková, Leona - Roubec, Jaromír - Černovská, Markéta - Salajka, František - Krejčí, Jana - Havel, Libor - Tomíšková, Marcela - Šatánková, Monika - Benejová, Andrea - Grygárková, Ivona - Hrnčiarik, Michal - Zemanová, Milada - Sixtová, Dimka - Merta, Zdeněk
PY - 2017
TI - Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic
KW - NSCLC
N2 - Background and Aim: From October 2013 there is a possibility to treat patients with NSCLC and with activated epidermal growth factor receptor (EGFR) mutations with three TKI (afatinib, eriotinib, gefitinib) in the Czech Republic. We have tried to find differences among patient groups treated with single TKI in 1st line of treatment. Patients and methods: As data source we used the TULUNG registry, which is focused on the data collection of patients with NSCLC treated with target therapy in the Czech Republic. We analysed 232 patients (gefitinib - 115 patients, afatinib - 77 patients, eriotinib - 40 patients.). Statistical significance was assessed using the Fisher's exact test or Kruskal-Wallis test (a=0.05).
ER -
SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Karel HEJDUK, Miloš PEŠEK, Vítězslav KOLEK, Leona KOUBKOVÁ, Jaromír ROUBEC, Markéta ČERNOVSKÁ, František SALAJKA, Jana KREJČÍ, Libor HAVEL, Marcela TOMÍŠKOVÁ, Monika ŠATÁNKOVÁ, Andrea BENEJOVÁ, Ivona GRYGÁRKOVÁ, Michal HRNČIARIK, Milada ZEMANOVÁ, Dimka SIXTOVÁ and Zdeněk MERTA. Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic. In \textit{ERS international Congress 2017}. 2017. ISSN~0903-1936.
|
